Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
FDA Biosimilar Pathways, Scientific Review, and Approval Standards
Description
The transcript explains FDA biosimilar regulation, scientific review, and approval standards. It notes the growing U.S. biosimilar landscape, with many approved and marketed products, significant patient use, and large estimated savings. The speaker reviews what biologics are, emphasizing their size, complexity, and inherent variability because they are made in living systems. FDA’s two pathways are contrasted: the original 351(a) standalone pathway for demonstrating safety and efficacy of a new biologic, and the abbreviated biosimilar pathway created by BPCI Act for products shown to be highly similar to a reference product with no clinically meaningful differences. Interchangeable products must also be expected to produce the same clinical results and, for repeat-use products, not increase risk or reduce effectiveness with switching; interchangeability allows pharmacy substitution under state law. The FDA relies on a totality-of-the-evidence approach, centered on extensive comparative analytical assessments using state-of-the-art, sensitive, orthogonal methods across many product attributes, plus comparative pharmacokinetic and immunogenicity data. The talk stresses that abbreviated does not mean lower standards: approved biosimilars are as safe and effective as reference products. It also explains that comparative efficacy studies are now often unnecessary when analytics and PK data are robust, reflecting evolving FDA and international regulatory thinking. Finally, the presentation highlights examples in dermatology, discusses labeling considerations, and reiterates that biosimilars and interchangeables can differ in presentation or indications but remain clinically comparable to their reference products.
View moreConclusions
- FDA-approved biosimilars are considered as safe and effective as their reference products, with no clinically meaningful differences expected in clinical use.
- The comparative analytical assessment is the scientific foundation of biosimilar evaluation and is often more sensitive than clinical efficacy studies for detecting differences.
- In many cases, a well-designed pharmacokinetic similarity study plus immunogenicity assessment is sufficient to support biosimilarity, making comparative efficacy studies unnecessary.
- Interchangeability is an added U.S.-specific designation that allows pharmacy-level substitution, but it does not imply a higher standard of clinical quality than biosimilarity itself.
- Biologic products naturally have inherent variability, so biosimilar evaluation focuses on demonstrating controlled similarity rather than exact identity.
- The biosimilar regulatory pathway is abbreviated compared with the standalone pathway, but the approval standards remain rigorous and product-specific.
- Because biosimilars can differ in labeling, presentation, or approved indications from their reference products, prescribers must review the biosimilar-specific prescribing information.
- Biosimilars have already generated substantial U.S. healthcare savings and expanded patient access, indicating that the market and clinical value of these products are significant.
- Regulators in the U.S. and other regions are moving toward streamlined development frameworks that rely less on comparative efficacy studies when analytical and PK evidence are strong.
- The current and near-future dermatology biosimilar landscape suggests growing treatment options, including more biosimilar and interchangeable products as reference products lose exclusivity.
- Mellstedt (2013), EJC Suppl. DOI: 10.1016/S1359-6349(13)70001-6#10.1016/S1359-6349(13)70001-6
- Welch et al., 2024, AAPS Open
- Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product (December 2016)
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (October 2025)
- European Medicines Agency draft reflection paper on a tailored clinical approach in biosimilar development
- Health Canada revised draft information and submission requirements for biosimilar biologic drugs
- ICH M18: framework for determining the utility of comparative efficacy studies in biosimilar development